Therapeutic attributes | Levels |
---|---|
Clinical effects (average): average years of delay in progression to moderate stage of Alzheimer’s disease, compared to standard of care | • 1.5 years • 2.5 years • 3.5 years |
Clinical effects (variation): distribution in the magnitude of clinical effects achieved among patients | • Narrow
• Wide
|
Biomarker response (amyloid clearance): proportion of patients achieving amyloid negativity on PET scan at 1 year | • 3 in 10 patients (30%) • 7 in 10 patients (70%) |
Adverse events (symptomatic ARIA-E): proportion of patients developing symptomatic ARIA-E during treatment | • 1 in 100 patients (1%) • 1 in 20 patients (5%) • 1 in 4 patients (25%) |
Treatment duration: total length of entire treatment course | • 1 year • 3 years • 5 years |
Treatment titration (at initiation): requirement to adjust dosage of medication when first starting treatment | • Does not require dosage titration • Requires dosage titration (typically for 3–8 months) |
Treatment administration: route and frequency of medication administration | • Intravenous every 2 weeks • Intravenous every 4 weeks • Subcutaneous every 2 weeks |